AKT1 and cancer: Moreover, the effects of the inhibition of the PI3K/Akt/mTOR pathway can be circumvented in cancer cells through the Raf/MEK/ERK signaling system [200], which may protect malignant cells from drug-induced proapoptotic injuries and, therefore, produce chemoresistant cancer cells variants [200].